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Bone Marrow-Derived Mesenchymal Stem Cells
Become Antiangiogenic When Chondrogenically
or Osteogenically Differentiated:
Implications for Bone and Cartilage Tissue EngineeringAU1c
AU2c Jennifer J. Bara, PhD,1 Helen E. McCarthy, PhD,2 Emma Humphrey, PhD,3
William E.B. Johnson, PhD,4 and Sally Roberts, PhD5
Osteochondral tissue repair requires formation of vascularised bone and avascular cartilage. Mesenchymal stem
cells stimulate angiogenesis both in vitro and in vivo but it is not known if these proangiogenic properties change
as a result of chondrogenic or osteogenic differentiation. We investigated the angiogenic/antiangiogenic
properties of equine bone marrow-derived mesenchymal stem cells (eBMSCs) before and after differentiation
in vitro. Conditioned media from chondrogenic and osteogenic cell pellets and undifferentiated cells was applied
to endothelial tube formation assays using Matrigel. Additionally, the cell secretome was analysed using
LC-MS/MS mass spectrometry and screened for angiogenesis and neurogenesis-related factors using protein
arrays. Endothelial tube-like formation was supported by conditioned media from undifferentiated eBMSCs.
Conversely, chondrogenic and osteogenic conditioned media was antiangiogenic as shown by significantly
decreased length of endothelial tube-like structures and degree of branching compared to controls. Un-
differentiated cells produced higher levels of angiogenesis-related proteins compared to chondrogenic and
osteogenic pellets. In summary, eBMSCs produce an array of angiogenesis-related proteins and support an-
giogenesis in vitro via a paracrine mechanism. However, when these cells are differentiated chondrogenically or
osteogenically, they produce a soluble factor(s) that inhibits angiogenesis. With respect to osteochondral tissue
engineering, this may be beneficial for avascular articular cartilage formation but unfavourable for bone for-
mation where a vascularised tissue is desired.
Introduction
The clinical success of osteochondral tissue engineer-ing relies upon the generation of a functional tissue of
physiologically relevant size that is capable of integration at
the repair site. Bone has an extensive blood supply that is
critical to the tissue’s viability and function. In the clinic,
disruption or lack of blood supply to bone causes osteone-
crosis and is implicated in the pathogenesis of nonunion
fractures.1 Conversely, the presence of blood vessels in ar-
ticular cartilage is associated with various pathologies, in-
cluding osteoarthritis2,3 rheumatoid arthritis,4 and inferior
repair tissue in autologous chondrocyte implantation.5 One
approach to osteochondral tissue engineering is to create a
biphasic construct in vitro whereby constituent cells have
reached a suitable level of chondrogenic and osteogenic
differentiation before implantation.6 However, nutritional
limitations posed by diffusion gradients currently limit the
size of viable tissues that can be engineered.7–9 Moreover, the
viability and successful integration of such constructs into
osteochondral defects relies upon vascular ingrowth after
in vivo implantation. Therefore, much attention is now fo-
cused on tissue engineering vascularised constructs. Current
strategies include incorporating vascular cell types,10,11 or
the addition of slow release angiogenic growth factors bound
to scaffolds.12,13 Vascularised bone constructs have also been
engineered in vivo by endocultivation, whereby a construct is
implanted intramuscularly to allow vascular ingrowth before
reimplantation into the defect site.14
Bone marrow-derived mesenchymal stem cells (BMSCs)
represent a potential cell source for osteochondral tissue
engineering. In the clinic, implantation of in vitro expanded
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BMSCs has been used to repair long bone15,16 and cartilage
defects.17–19 However, it is not clear if, or how, in vitro dif-
ferentiated BMSCs may affect vascular ingrowth once re-
implanted into osteochondral defects. Undifferentiated
BMSCs elicit potent angiogenic effects which appear to be
due to a combination of direct cellular interactions and by
the release of soluble factors. In vitro, BMSCs secreteAU3c VEGF,
FGF-2, interleukin-6,AU4c PIGF, angiopoeitin-1,AU3c PDGF, plasmin-
ogen activator,AU3c MMP-9 and monocyte chemotactic protein-1
(MCP-1).20,21 BMSC conditioned media stimulates endo-
thelial cell proliferation and migration20 and tube-like
formation.21 Neutralising antibody experiments have dem-
onstrated that the mitogenic effects of BMSC secretome were
not solely due to the presence of one particular growth fac-
tor, but a combination of factors.20 In vivo, improved vascular
ingrowth and osteogenesis at the fracture site was observed
after implantation of gelatin sponges containing MSC con-
ditioned media in rats.22 Similarly, injection of BMSC con-
ditioned media improved blood flow in a mouse model of
hindlimb ischaemia.20 BMSCs have also been reported to
stimulate vascularisation in animal models of myocardial
infarction.23,24 Conversely, there is also evidence to suggest
that BMSCs may inhibit angiogenesis. Otsu et al. reported
that direct cell–cell contact between rat BMSCs and endo-
thelial cells caused apoptosis and destruction of endothelial
tube-like structures on Matrigel. Furthermore, in their
mouse melanoma model, BMSCs appeared to abrogate tu-
mour growth by inhibiting tumour angiogenesis.25
It is currently unknown whether these predominantly
proangiogenic properties of undifferentiated BMSCs are
conserved after in vitro chondrogenic or osteogenic differ-
entiation and the accompanying change from a 2D to 3D
environment. In the present study, equine BMSCs (eBMSCs)
were differentiated along chondrogenic and osteogenic lin-
eages in 3D pellet culture as previously described.26 Angio-
genic properties of undifferentiated and differentiated cells
were analyzed by collecting serum-free conditioned media
and (1) screening it for angiogenesis-related proteins and (2)
applying it to an in vitro angiogenesis assay, which measures
the degree of endothelial tube-like formation on Matrigel.
Our results show that conditioned media from undifferenti-
ated eBMSCs supports endothelial tube-like formation
in vitro and contains an array of angiogenic, antiangiogenic
and neurotrophic factors. We present novel data showing
that when differentiated along chondrogenic and osteogenic
lineages, eBMSCs reduce production of angiogenesis and
neurogenesis-related proteins and produce a soluble factor(s)
that inhibits endothelial tube-like formation in vitro.
Materials and Methods
Cell culture
eBMSCs were isolated from the bone marrow of the third
metacarpal of distal forelimbs from four horses (mean age 7
years) as previously described.26 Four days after isolation,
flasks were washed to ensure removal of haematopoietic
cells. eBMSCs were incubated at 37C at 5% CO2 and re-
ceived media changes with eBMSC medium (DMEM +
GlutaMAXTM-1, 100mg mL- 1 gentamicin, 10% foetal calf se-
rum [FCS] [PAA]) three times a week. At each passage,
population doublings were calculated using the following
formula: LOG10 (final cell number/initial cell number))*3.33.
Subsequent differentiation assays and generation of condi-
tioned media were performed using eBMSCs that had un-
dergone approximately 25 population doublings (p2–3).
Monolayer adipogenic and osteogenic differentiation
eBMSCs were seeded into six-well plates at 3 · 103 cells/
cm2 and cultured in eBMSC medium until 80% confluent. For
adipogenesis, cells were incubated with adipogenic media
(DMEM +GlutaMAXTM-1, 100 mg mL - 1 gentamicin, 10mg
mL - 1 insulin [Sigma], 1 mM dexamethasone [Sigma], 100mM
indomethacin [Sigma], 500mM 3-isobutyl-1-methyl xanthine
[Sigma] and 15% normal rabbit serum [Sigma]) for 6 days.
Cells were fixed in 10% formalin and treated with 0.5% Oil
red O (Sigma) in 60% IPA for 1 h.
For osteogenesis, eBMSCs were incubated for 21 days with
DMEM +GlutaMAXTM-1, 0.1mM L-ascorbic-acid-2-phos-
phate (Sigma), 100mg mL - 1 gentamicin, 10 nM dexametha-
sone, 10mM b-glycerophosphate (Sigma), and 10% FCS.
Cells were fixed with 10% formalin and treated with the
following solution for 1 h in to detect alkaline phosphatase
activity: 10% naphthol solution (50mg mL - 1 napthol AS-BI
phosphate [Sigma] in dimethyl formamide [BDH] pH 8) in
0.2M Tris–HCl (Sigma) buffer pH 9 + 1mg mL- 1 Fast Red
TR (Gurr). eBMSCs treated with standard eBMSC media
served as controls.
Chondrogenic and osteogenic differentiation
in 3D pellet culture
eBMSCs were chondrogenically and osteogenically dif-
ferentiated in defined media using a previously described
pellet culture system.26 To make cell pellets, eBMSCs, sus-
pended in either chondrogenic or osteogenic differentiation
media, were transferred into 1.5mL Eppendorf tubes
(0.5 · 106 cells per Eppendorf) and centrifuged at 500 g for
5min. Chondrogenic differentiation medium consisted of:
DMEM +GlutaMAXTM-1, 2% FCS, 100 mg mL - 1 gentamicin,
10 mg mL - 1 Insulin-Transferrin-Selenium-X (Gibco), 0.1mM
L-ascorbic-acid-2-phosphate, 10 nM dexamethasone and
10 ng mL - 1 TGF-b1 (Peprotech). Osteogenic differentiation
medium was as described for monolayer differentiation.
Pellets were incubated at 37C and 5% CO2 for 21 days with
media changes three times a week.
Generation of conditioned media
Serum-free conditioned media was generated from un-
differentiated cells, chondrogenic and osteogenic pellet cul-
tures of eBMSCs.27 Undifferentiated eBMSCs were cultured
until 70% confluent, washed twice with phosphate-buffered
saline (PBS) and incubated with 20mL of conditioning media
(serum free DMEM +GlutaMAXTM-1, 100mg mL - 1 gentami-
cin supplemented with 10mg mL- 1 Insulin-Transferrin-
Selenium-X and 1% MEM nonessential amino acids [Gibco])
per T75 flask. Conditioning media was incubated with cells
for 4 days, filtered through a 0.45 mm filter (Sarstedt) and
stored at - 20C. Upon collection of conditioned media, cells
were passaged and a cell count performed. For chondro-
genic/osteogenic pellets, at day 21, pellets were washed
twice in PBS and incubated with 1mL of conditioning media
per pellet. Conditioned media was collected after 4 days and
processed as described above. Pellets were snap frozen in
liquid nitrogen cooled hexane and stored at - 80C.
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Histological and immunohistochemical analysis
of pellet cultures
Histology and immunohistochemistry was performed on
7 mm cryosections from a minimum of four pellets per horse
(16 chondrogenic & 16 osteogenic). Toluidine blue was ap-
plied to cryosections for 1min, washed and air dried over-
night before being mounted in Pertex (Histolab). For Von
Kossa staining, 5% silver nitrate (VWR) in distilled water
was applied to cryosections and placed under a UV light
until brown colour development (*2min). Sections were
washed with 2% sodium thiosulphate (BDH) in distilled
water, dehydrated then mounted with Pertex.
Immunohistochemistry was carried out at room temper-
ature unless otherwise stated. For type II collagen, cryosec-
tions were pretreated with 4800U/mL ovine testicular
hyaluronidase (Sigma) and 0.25U/mL chondroitinase ABC
(MP Biomedicals) in Tris acetate buffer pH 8 for 2 h. Sections
were fixed in 10% formalin, blocked with 5% goat serum
(Vector), then incubated with mouse anticollagen type II
(CIIC1, DSHB) (1:10 in PBS) overnight at 4C. Negative
controls were incubated with mouse IgG1a (Dako). The
secondary antibody goat anti-mouse Alex Fluor 488 (In-
vitrogen) (1:200 in PBS) was applied to sections for 1 h. After
washing in PBS, sections were mounted with Vectashield
mounting medium for fluorescence containing DAPI (Vec-
tor) and observed using a Leitz Diaplan light microscope. For
type X collagen, cryosections were fixed in a solution of
methanol and acetone for 10min, washed in PBS, then
treated with 1mg/mL protease in PBS (Sigma; P-6911) for
30min. Sections were blocked with 5% bovine serum albumin
(BSA) in PBS for 30min, then incubated with mouse antic-
ollagen type X antibody (a kind gift from Gary J. Gibson,
Henry Ford Hospital, Detroit, MI) (1:300 in PBS containing 1%
BSA) overnight at 4C. An isotype matched mouse immuno-
globulin was used as a negative control. Sections were incu-
bated with goat anti-mouse Alexa Fluor 594 (Invitrogen)
(1:200 in PBS containing 1% BSA) for 45min. Slides were
washed in PBS then mounted with Vectashield mounting
medium for fluorescence containing DAPI (Vector) and ob-
served using Leica TCS SP2 AOBS confocal microscope.
DNA quantification assay
DNA content of undifferentiated, chondrogenically and
osteogenically differentiated eBMSCs that generated a stan-
dard volume of conditioned media was calculated using the
Quanti-iT PicoGreen assay (Invitrogen). Pellets/undif-
ferentiated eBMSCs were digested in 1.25mg/mL Proteinase
K (Sigma) in 100mM ammonium acetate (Sigma) containing
7% EDTA (BDH) in distilled water, at pH 7 at 60C over-
night. Briefly, 200mL of pellet/cell digest were diluted in
Tris–EDTA buffer and pipetted in triplicate into a 96-well
plate. PicoGreen reagent was incubated with samples for
5min at room temperature. Fluorescence was measured us-
ing a fluorescent microplate reader (FLx800 microplate
fluorescence reader; Bio-Tek Instruments) at (excitation
wavelength 480 nm, emission wavelength 520 nm).
Angiogenesis array
A sample of conditioned media from undifferentiated,
chondrogenically, and osteogenically differentiated eBMSCs
from each horse was screened for angiogenesis-related pro-
teins using a Human Angiogenesis Proteome Profiler an-
tibody array (R&D Systems) according to the manufacturer’s
instructions. Positive signals were detected by chemilumi-
nescence (UptiLight US WBlot HRP chemiluminescent de-
tection reagent; Interchim) and visualised with ChemiDOc
EQ (Bio-Rad). Array data was quantified by measuring the
sum of the intensities of the pixels within the spot bound-
ary·pixel area with image analysis software (Quantity One
version 4.6.3; Bio-Rad). Array data was normalized to
background then DNA content as calculated for each culture
from each respective horse.
Endothelial tube-like formation assay
Endothelial tube-like formation assays were performed
using Matrigel (growth factor reduced, phenol red-free [BD
Biosciences]). Twenty-four-well tissue culture plates were
coated with 230 mL Matrigel per well and allowed to solidify
at 37C for 30min. The human dermal microvascular cell
line, HMEC-1, was seeded onto Matrigel (1 · 105 per well) in
MCDB 131 medium, 0.05% penicillin and streptomycin (both
Gibco) and 10% FCS. After 4 h plates were washed gently
thrice before application of either undifferentiated, chon-
drogenically or osteogenically differentiated eBMSC condi-
tioned media. Conditioning media that had not been in
contact with cells was used for controls. Time lapse images
were captured over a 24 h period using a video camera set up
to an Olympus CK2 microscope. After 24 h, wells were wa-
shed and viewed in phase using a Nikon TS100 fluorescent
microscope.
Total tube length in five fields of view per well was
quantified by drawing over and measuring tube-like struc-
tures using image analysis software (IPLab version 3.6;
Becton Dickinson) ( b F1Fig. 1A). Complexity of tube-like net-
works was scored using an adapted scoring system by
Mcilroy et al. (Fig. 1B).28 Two cells sharing a common
branching point were scored as 1 (‘‘a’’ in Fig. 1B); three cells
sharing a common branching point were scored as 2 (‘‘b’’ in
Fig. 1B) and so on. Angiogenic sprouts, classified as an un-
connected tube-like structure 25–100mm in length were
scored as 1. Data for total tube length and branching score
were normalized to the DNA content calculated for each
culture from each respective horse.
Mass spectrometry
Undifferentiated, chondrogenically, and osteogenically
differentiated eBMSC conditioned media from three horses
was analysed by LC-MS/MS mass spectrometry. Condi-
tioned media was concentrated 10 ·using Amicon Ultra-2
centrifugal filter devices (10 kDa molecular weight cut off)
according to the manufacturer’s instructions (Millipore), di-
gested with trypsin at 37C then separated by liquid chro-
matography. MS/MS analysis was performed on
fractionated peptides using a 4800 MALDI TOF/TOF mass
spectrometer (Applied Biosystems). The search engine
‘‘MASCOT’’ was used to identify peptides from the NCBI
database. Peptides with a total ion score > 95% confidence
interval or with a peptide count of > 2 were excluded. Un-
amed or hypothetical proteins were identified using an on-
line bioinformatics database (DAVID).
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Statistical analysis
With the exception of growth kinetics, data from all horses
were pooled before statistical analysis. Differences between
treatment groups and controls were tested for statistical
significance using Analyse-it. All data presented a non-
normal distribution as determined using the Anderson
Darling test for normality and Levene’s test for equality of
variances. Data from the three treatment groups were tested
for significant differences using a Kruskal–Wallis one-way
analysis of variance test.
Results
Growth kinetics and mutipotency of eBMSCs
eBMSCs demonstrated a characteristic ‘‘MSC’’ morphol-
ogy and grew rapidly, undergoing approximately 20 popu-
lation doublings in the first 12 days of culture ( b F2Fig. 2A).
eBMSCs from all 4 horses demonstrated adipogenic and
osteogenic differentiation in 2D differentiation assays. Ad-
piogenic differentation of eBMSCs was confirmed by the
presence of intracellular lipid droplets as shown by oil red O
staining (Fig. 2B, C). Differentiated cells were larger and less
bipolar in morphology compared to controls. Osteogenic
differentiation of eBMSCs was indicated by the presence of
alkaline phosphatase (Fig. 2D, E). Notably, differentiated
cells lost their bipolar morphology, became larger and
demonstrated a jagged-like border.
eBMSCs chondrogenically and osteogenicially
differentiated in pellet culture
Osteogenic pellets stained intensely pink with eosin ( b F3Fig.
3A), suggesting mineralisation, compared to chondrogenic
pellets where staining was paler (Fig. 3B). Osteogenic pellets
contained little sulphated glycosaminoglycan (sGAG) (Fig.
3C), whereas chondrogenic pellets demonstrated strong
metachromatic staining with toluidine blue indicating a
sGAG-rich matrix (Fig. 3D). All osteogenic pellets displayed
a mineralised matrix as shown by Von Kossa staining (Fig.
3E). In contrast, none of the chondrogenic pellets stained
positively with Von Kossa (Fig. 3F). Immunohistochemistry
demonstrated positive labelling of type II collagen in chon-
drogenic pellet cultures (Fig. 3G–H). Type X collagen was
detected in discrete regions of chondrogenic pellets (Fig. 3J),
as confirmed by an equine growth plate positive control
(Fig. 3K). Neither collagen type II or type X were found
immunohistochemically in osteogenic pellets (not shown).
Appropriately matched isotype controls for both type II
and type X collagen antibodies were negative (Fig. 3I, L,
respectively).
Conditioned media from chondrogenically
and osteogenically differentiated eBMSCs
inhibited endothelial tube-like formation
HMEC-1 formed complex networks of tube-like structures
when seeded onto Matrigel ( b F4Fig. 4). A time course of images
showing tube-like formation may be viewed in b SF1Supplemen-
tary Figure S1 bAU5(Supplementary Data are available online at
www.liebertpub.com/tea). Fewer tube-like networks formed
when HMEC-1 were cultured for 24 h with either chondro-
genic (Fig. 4A) or osteogenic (Fig. 4B) conditioned media
compared to both controls (conditioned media from undif-
ferentiated cells and control media that had not been in
contact with cells). Total tube length (Fig. 4E) and branching
score (Fig. 4F) were significantly less when endothelial cells
were cultured with chondrogenic or osteogenic conditioned
media compared to controls (Fig. 4E, all comparisons:
p < 0.0001, Kruskal–Wallis).
Chondrogenically and osteogenically differentiated
eBMSCs reduced production of both angiogenic
and antiangiogenic proteins
Conditioned media from undifferentiated, chondro-
genically and osteogenically differentiated eBMSCs was
screened for the presence of angiogenic/antiangiogenic fac-
tors using an antibody array, which detects the relative levels
FIG. 1. Analysis of endothelial tube-like formation. (A)
Lengths of tube-like structures were drawn manually over the
image (shown in red). Total tube-like length per field of view
was automatically measured using image analysis software
(IPLab version 3.6, Becton Dickinson). (B) Complexity of tube-
like networks scored using an adapted scoring system by
Mcilroy et al., which measures cell branch points. (a) Two (b)
Three cells sharing a common branching point were scored as 1
and 2, respectively. (c) Angiogenic sprouts, classified as un-
connected tube-like structure 25–100mm in length were scored
as 1. Color images available online at www.liebertpub.com/tea
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of 55 different angiogenesis related proteins. Six angiogenic
(DPPIV, MMP-9, endothelin-1, PDGF-AA,AU4c UPA, and VEGF)
and four antiangiogenic proteins (TIMP-1, IGFBP-2, PF4 and
angiopoietin-2) were detected at higher levels compared to
all other proteins (F5c Fig. 5A, E, respectively). Undifferentiated
eBMSC conditioned media contained significantly higher
levels of angiogenesis-related proteins compared to chon-
drogenic and osteogenic conditioned media, with the ex-
ception of DPPIV, VEGF, and PDGF-AA, which were not
significantly different between undifferentiated and chon-
drogenic conditioned media (Fig. 5A–G). Interestingly,
chondrogenic conditioned media contained higher levels of
angiogenic factors, PDGF-AA ( p= 0.0079), VEGF ( p= 0.0497),
FGF-2 ( p= 0.0363), FGF-4 ( p= 0.0126), FGF-7 ( p= 0.0225),
MCP-1 ( p= 0.0363) and activin A ( p= 0.0230), and the anti-
angiogenic factor, IGFBP-3 ( p= 0.0188), compared to osteo-
genic conditioned media.
Chondrogenically and osteogenically differentiated
eBMSCs reduced production of neurotrophic proteins
Undifferentiated eBMSC conditioned media also con-
tained higher levels of neurogenic factors compared to
chondrogenic and osteogenic secretome (Fig. 5H). Levels of
artemin were significantly higher in undifferentiated com-
pared to both chondrogenic ( p= 0.0209) and osteogenic
( p = 0.0079) conditioned media. Undifferentiated eBMSC se-
cretome contained significantly more persephin than osteo-
genic conditoned media ( p = 0.0044). Both chondrogenic
( p = 0.0126) and osteogenic ( p = 0.0002) conditoned media
FIG. 2. Multipotent phenotype
of equine bone marrow-derived
mesenchymal stem cells
(eBMSCs). (A) Population dou-
blings against time in culture.
Each data series represents a cell
population isolated from a dif-
ferent horse. Oil red O staining
of lipid droplets in (B) adipo-
genically differentiated and (C)
undifferentiated control
eBMSCs. Alkaline phosphatase
staining of (D) osteogenically
differentiated and (E) undiffer-
entiated control eBMSCs. Scale
bars 100 mm. Color images
available online at www
.liebertpub.com/tea
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contained less glial cell-derived neurotrophic factor (GDNF)
compared to undifferentiated conditioned media, with chon-
drogenic conditioned media containing higher levels of the
neurotrophin compared to osteogenic secretome ( p= 0.0363).
Proteomic analysis of eBMSC conditioned media
After applying a stringent set of exclusion criteria, almost
all peptides detected in eBMSC conditioned media by mass
spectrometry were identified as ECM proteins. Type I col-
lagen peptides were identified in all samples (T1c Table 1).
Chondrogenic conditioned media contained multiple fibro-
nectin peptides. Fibronectin was also detected in the secre-
tome of undifferentiated and osteogenically differentiated
eBMSCs (two of the three BMSC populations tested). Pep-
tides of cartilage-associated matrix proteins biglycan and
decorin were identified in chondrogenic conditioned media.
Similary, type II collagen and lumican were identified in two
out of the three samples of chondrogenic secretome. The
presence of these peptides are indicative of a cartilaginous
ECM; thus, further confirming the chondrogenic phenotype
of differentiated eBMSCs. Peptides of the antiangiogenic
molecule thrombospondin were detected in two out of three
samples of chondrogenic and in one sample of both undif-
ferentiated and osteogenic conditioned media. Bone sialo-
protein-2 was also present in the chondrogenic conditioned
media from two out of the three BMSC populations tested
and at 94.6% confidence interval in the third sample.
Discussion
In the present study, we show for the first time, that when
either chondrogenically or osteogenically differentiated in a
3D culture system, eBMSCs reduce production of angio-
genesis and neurogenesis-related proteins and inhibit an-
giogenesis in vitro. With respect to osteochondral tissue
engineering, this supports the use of BMSCs for avascular
cartilage formation; however, maybe of concern for the
generation of vascularised bone.
Initially, eBMSCs proliferated rapidly in culture, which is
concominant with other studies examining the growth ki-
netics of eBMSCs in vitro.26,29 We have previously shown
that these cells express the putative stem cell markers CD90,
CD166 and STRO-1.26 eBMSCs demonstrated multipotency
FIG. 3.AU7c Haematoxylin and
eosin staining of (A) osteo-
genic and (B) chondrogenic
pellets. Metachromasia of (C)
osteogenic and (D) chondro-
genic pellets using toluidine
blue indicates a sulphated
glycosaminoglycan rich ma-
trix in chondrogenic pellets.
(E) Osteogenic pellets stained
strongly with Von Kossa in-
dicating a calcium rich mi-
neralised matrix, whereas
chondrogenic pellets ap-
peared unmineralised (F). (G–
L) Immunohistochemical
analysis of type II and X col-
lagen inAU7c chondrogenic pellet
cultures. Chondrogenic pellets
labelled positively but vari-
ably for type II (G–H) and
type X ( J) collagen. Equine
growth plate type X collagen
positive control (K). IgG and
IgM controls were negative
for type II (I) and X (L) colla-
gen, respectively. Cell nuclei
counterstained blue with
DAPI, scale bars are 100mm
unless stated otherwise. Color
images available online at
www.liebertpub.com/tea
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as shown by their ability to differentiate along adipogenic,
osteogenic and chondrogenic lineages. In addition to stan-
dard differentiation in monolayer, osteogenic differentiation
was performed in a 3D pellet culture system as previously
described.30 Mineralization of osteogenic pellets shown by
Von Kossa and haematoxylin and eosin suggest that eBMSCs
differentiated osteogenically. Previous 3D osteogenic differ-
entiation of these cells has also identified the presence of
osteocalcin immunohistochemically.26
Chondrogenic differentiation was demonstrated by the
presence of sGAG and type II collagen; however, discrete
regions of type X collagen immunostaining indicate areas of
hypertrophy. This, together with the identification of bone
sialoprotein in chondrogenic conditioned media, suggest
differentiation of eBMSCs toward a hypertrophic phenotype.
Hypertrophy of chondrogenically differentiated BMSCs in
pellet culture is widely reported in the literature.26,31–34 In
endochondral ossification, hypertrophic chondrocytes are
proangiogenic, producing VEGF, which leads to vascular
invasion and ossification of the cartilage anlagen.35 Although
we observed a degree of hypertrophy, chondrogenic eBMSC
secretome was antiangiogenic. Our findings highlight im-
portant differences between the phenotypes of nascent hy-
pertrophic chondrocytes compared to MSC that have been
manipulated to differentiate chondrogenically in vitro.
Conditioned media from undifferentiated eBMSCs sup-
ported the formation of endothelial tube-like structures,
although this was comparable to controls. This suggests
angiogenic factors detected in undifferentiated eBMSC con-
ditioned media did not further enhance tube-like formation.
FIG. 4. Matrigel assays 24 h after treatment with eBMSC conditioned media. Representative images showing endothelial
tube-like formation after treatment with (A) chondrogenic, (B) osteogenic, (C) undifferentiated, and (D) control conditioned
media. (E) Tube-like length and (F) branching score were significantly greater when endothelial cells were cultured with
control media or undifferentiated eBMSC conditioned media compared to both chondrogenic and osteogenic conditioned
media. Data shown are medians, error bars represent minimal and maximal data points (***p< 0.0001, Kruskal–Wallis, n = 12).
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FIG. 5. Angiogenic, antiangiogenic, and neurotrophic factors identified in eBMSC conditioned media, normalised to DNA
content. Undifferentiated eBMSC secretome generally contained higher levels of angiogenic, antiangiogenic, and neuro-
trophic factors compared to both chondrogenic and osteogenic conditioned media. (A) Six angiogenic (Dipeptidyl Peptidase
IV [DPPIV], bAU3MMP-9, endothelin-1,
bAU8
PDGF-AA, UPA, and VEGF) and (E) four antiangiogenic (TIMP-1, insulin-like growth
factor binding protein-2 [IGFBP-2], platelet factor-4 [PF4], angiopoietin-2) were detected at high levels compared to all other
proteins. Conditioned media from chondrogenically differentiated eBMSCs contained higher levels of angiogenic factors
PDGF-AA ( p = 0.0079), VEGF ( p= 0.0497), bAU3FGF-2 ( p = 0.0363), FGF-4 ( p = 0.0126), FGF-7 ( p = 0.0225), monocyte chemotactic
protein-1 (MCP-1) ( p = 0.0363), activin A ( p = 0.0230), the antiangiogenic factor IGFBP-3 ( p= 0.0188) and glial derived neu-
rotrophic factor (GDNF) ( p = 0.0363) compared to osteogenic conditioned media. Data shown are means – SEM (*p< 0.05,
**p< 0.01, Kruskal–Wallis, conditioned media from four horses [n= 4]).
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This is contrary to a study by Hung et al., who reported
stimulation of endothelial tube formation by human BMSC
secretome.21 Hung et al. used a different cell line and method
for the generation of conditioned media and performed the
Matrigel assay under hypoxic conditions, which could ac-
count for such discrepancies. Our data show significant in-
hibition of endothelial tube-like formation when HMEC-1
were cultured with conditioned media from chondro-
genically or osteogenically differentiated eBMSCs. eBMSCs
produced lower levels of antiangiogenic factors following
Table 1. Summary of Proteins Identified from Peptides Detected in Equine Bone
Marrow-Derived Stem Cell Conditioned Media by LC-MS/MS Mass Spectrometry
Peptides detected in eBMSC conditioned media by LC-MS/MS mass spectrometry
Peptide count
Peptide Accession number Horse 1 Horse 2 Horse 3
Undifferentiated
gij50978774 28 22 17
gij22328092 27 21 17
Collagen type I (multiple) gij27806257 14 10 20
gij50978940 17 10 17
gij32451581 10 8 15
gij111120329 8 7 10
gij2894106 14 11 —
gij16758080 7 — 13
gij470674 19 — 10
Collagen type V gij32822777 4 — 17
Procollagen alpha 2 (V) gij2370202 5 — 15
Type V preprocollagen alpha 2 chain gij16197600 5 — 17
Fibronectin gij31874109 — 7 5
Thrombospondin-1 gij37138 — 2 —
Chondrogenically differentiated
gij50978774 20 11 14
gij22328092 19 11 15
gij27806257 7 2 7
Collagen type I (multiple) gij50978940 9 — 6
gij16758080 4 — 6
gij32451581 5 — 9
gij2894106 — 5 9
gij179631 3 — 3
gij2497972 5 4 6
Fibronectin (multiple) gij1675365 2 3 3
gij31874109 8 7 —
Bone sialoprotein 2 gij160358833 2 2 1 (94.%CI)
Biglycan gij20137008 5 — 7
Collagen type II gij30410850 5 — 7
Clusterin gij126352584 — 3 3
Decorin (multiple) gij126352546 — 4 6
gij160333372 — 2 2
Lumican (multiple) gij57097203 — 4 5
gij21542114 — 3 3
Thrombospondin-1 (multiple) gij37138 — 2 —
gij899229 — — 2
Osteogenically differentiated
gij50978774 17 7 18
gij27806257 6 7 11
gij50978940 8 5 12
gij111120329 3 — 5
Collagen type I (multiple) gij2894106 — 7 11
gij22328092 — 7 18
gij470674 12 7 13
Clusterin gij126352584 4 — 4
Collagen type III gij56711254 2 — 4
Fibronectin (multiple) gij31874109 3 — 3
gij1675365 1 — 0
gij2497972 3 — 0
Thrombospondin-1 gij37465 1 — —
eBMSCs, equine bone marrow-derived mesenchymal stem cell; —, peptide not detected.
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differentiation; therefore, this antiangiogenic activity cannot
be accounted for by the presence of these inhibitory mole-
cules. Therefore, we propose, that differentiated cells pro-
duced one or more soluble factor(s) not present on our
protein-antibody arrays that inhibited endothelial cells by
either an angiogenic specific or nonspecific mechanism. It is
possible that antiangiogenic proteins previously reported in
cartilaginous tissues, such as chondromodulin36,37 may have
been responsible. Endothelial tube formation assays using
Matrigel are highly sensitive, reproducible assays, used to
model angiogenesis in vitro (reviewed by Staton et al.).38 We
used growth factor-reduced Matrigel, to avoid any interfer-
ence from endogenous factors. However, being composed of
murine tumor eCM proteins, Matrigel does not precisely
model the vascular microenvironment associated with os-
teochondral tissues. Species difference is also a noteworthy
consideration of our study (equine-human). Whether the
observed antiangiogenic effects of eBMSCs would be reca-
pitulated by human BMSCs in vivo is unclear and requires
further investigation.
With the aim of identifying this soluble antiangiogenic
factor(s), conditioned media was analysed by mass spec-
trometry. The only known antiangiogenic peptide identified
was thrombospondin in two samples of chondrogenic and in
one sample of osteogenic and undifferentiated conditioned
media, respectively. However, thrombospondin was de-
tected by protein-antibody array at higher levels in undif-
ferentiated compared to differentiated eBMSC secretome,
making it unlikely to be responsible for the inhibition of
endothelial tube-like formation. Mass spectrometry did not
identify any other angiogenesis-related proteins, which is
likely due to masking by more abundant ECM proteins, such
as the collagens.
Angiogenic factors have been previously identified in
undifferentiated BMSC conditioned media.20,21 The results
presented here demonstrate, for the first time, reduction of
angiogenesis-related proteins when BMSCs are differentiated
in a 3D culture system toward chondrogenic and osteogenic
lineages. This finding does not appear to have been reported
previously in the literature with any species of BMSC. It
could be argued that the change in culture environment ra-
ther than the differentiation status of the cells reduced se-
creted levels of angiogenesis-related proteins. However, this
is not supported by a previous study, which reported an
increase in production of angiogenic factors by BMSCs upon
transition from a 2D to 3D culture system.39 Moreover, our
data reveal significant differences in levels of angiogenesis-
related proteins between chondrogenic and osteogenic cul-
tures. Thus, it is clear that the state of cellular differentiation
affects the angiogenesis-related protein secretome profile of
eBMSCs. The effect of 2D versus 3D culture could be further
investigated by culturing eBMSC pellets in standard media
as a control. However, this is complicated by the fact that
BMSCs may spontaneously differentiate chondrogenically in
pellet culture in the absence of chondrogenic growth factors,
such as TGF-b.40,41
Angiogenesis and osteogenesis are coupled in vivo, which
is reflected by cross-talk between vascular and osteogenic
cell types in vitro (reviewed by Grellier et al.).42 Osteoblasts
produce VEGF,43 an important angiogenic growth factor,
which may also influence osteogenesis as it can function to
recruit osteoprogenitor cells and stimulate their differentiation
into osteoblasts.44,45 Recently, endothelial cells have been
shown to promote osteogenic differentiation of BMSCs in a 3D
spheroid coculture model.46 Thus, cellular communication
between bone/cartilage forming and vascular cells may not
only influence the vascularisation of osteochondral tissues but
may also affect repair tissue composition. Considering the
above, we were surprised to observe antiangiogenic properties
of osteogenically differentiated eBMSCs. However, our find-
ings are supported by a recent study in which BMSC secre-
tome reduced endothelial tube-like formation and angiogeneic
factor production after osteogenic differentiation in monolay-
er.47 Importantly, we and the aforementioned author exam-
ined the angiogenic properties of in vitro differentiated BMSCs
at one stage of cellular differentiation. It is possible that the
angiogenic properties of differentiating BMSCs change in a
temporal manner as the cells become more committed.
Our findings have important implications for the devel-
opment of vascularised osteochondral constructs, utilizing
the regenerative capacity of BMSCs. Antiangiogenic para-
crine activity of chondrogenically and osteogenically differ-
entiated BMSCs may prevent subchondral vascular ingrowth
upon in vivo transplantation into the defect site. This would
reduce viability, function, and integration of the osseous
portion of the construct and potentially compromise the
nutritional supply to the overlying articular cartilage. There
are several strategies that may negate this problem by pro-
moting vascularisation: (1) refine/manipulate osteogenic
differentiation of BMSCs to promote their angiogenic ca-
pacity (2) prevascularise the osseous portion of the construct
by either incorporating vascular cells10,11 or by intramuscular
endocultivation techniques14,48 or (3) angiogenic priming of
the osseous portion of the construct by slow release angio-
genic factor delivery systems.12,13,49
Undifferentiated human BMSCs elicit neurogenic effects,
which are attributed, in part, to production of neuro-
trophins.27,50–52 Here eBMSCs produced neurogenic proteins,
GDNF, NRG1-b1, persephin and artemin, when chon-
drogenically/osteogenically differentiated. The fact that
chondrogenic and osteogenic differentiation resulted in re-
duced angiogenic and neurogenic properties of eBMSCs is
noteworthy, since during development angiogenesis and
neurogenesis often occur simultaneously and are regulated
by similar molecular mechanisms.53,54 For future work it
would be interesting to investigate the effect of conditioned
media from chondrogenically and osteogenically differenti-
ated BMSCs on in vitro models of nerve growth and to ex-
amine potential interplay between soluble angiogenesis and
neurogenesis-related factors.
In conclusion, when either chondrogenically or osteogenically
differentiated, eBMSCs exert antiangiogenic effects by paracrine
activity. With respect to in vitro osteochondral tissue engineering
this would be beneficial for maintaining an avascular articular
cartilage but undesirable for bone formation. Future work in
this field is required to differentially regulate vascularisation
in tissue engineered bone and cartilage to improve os-
teochondral tissue engineering therapies for clinical use.
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SUPPLEMENTARY FIG. S1. Time lapse images of Matrigel assays taken over a 24 h period during treatment with equine
bone marrow-derived mesenchymal stem cells conditioned media. Representative images showing endothelial tube-like
formation after application of undifferentiated, osteogenic, and chondrogenic conditioned media. Scale bars 100mm.
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